Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q15/00—Anti-perspirants or body deodorants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof

Definitions

• the invention relates to cosmetic compositions and methods for treating body odours, in particular axillary odours, the methods comprising the application to the keratinous substances of a composition comprising at least one bacteriocin in a cosmetically acceptable medium.
• Antiperspirant substances operate by limiting the flow of sweat. They are generally composed of aluminium salts which may irritate the skin and which reduce the flow of sweat by modifying the cutaneous physiology, which is not satisfactory.
• Bactericidal substances inhibit the development of the skin flora responsible for axillary odours.
• the one most commonly used is triclosan (2,4,4'-trichloro-2'-hydroxydiphenyl ether), which has the drawback of considerably modifying the ecology of skin flora and of being inhibited by certain compounds commonly used in the formulation of cosmetic compositions, for instance by nonionic surfactants.
• Axillary microflora is mainly composed of Gram+ bacteria, such as staphylococci (e.g. S. epidermidis, S. hominis, etc.), coryneforms (more particularly C. xerosis), or micrococci (e.g. M. Luteus), Brevibacteria and Propionibacteria.
• Unpleasant axillary odours are attributed to the microbial bioconversion of the natural secretions, which are odourless, into odorous volatile products.
• the strong axillary odours are mainly linked to the presence of C. xerosis in this region.
• the bactericidal products conventionally used for the purpose of obtaining good deodorant effectiveness lead to the destruction, without distinction, of the entire skin flora.
• active ingredients are sought which have a more specific action against the microorganisms responsible for unpleasant odours, and, moreover, which are friendly to the beneficial microorganisms not responsible for these annoyances.
• Patent US 5,318,778 proposes the use of lantibiotics in deodorant compositions. There remains, however, the need to find improved treatments for unpleasant body odours related to human perspiration, in particular axillary odours.
• the applicant has discovered, surprisingly and unexpectedly, that, by using a class II bacteriocin in a composition, it is possible to obtain an effective deodorant activity.
• An aspect of the present invention is therefore a cosmetic method for treating body odours, in particular axillary odours, comprising the application to the keratinous substances of a composition comprising at least one class II bacteriocin in a cosmetically acceptable medium.
• An aspect of the present invention is also the use of a class II bacteriocin as a deodorant agent.
• cosmetically acceptable is intended to mean which is compatible with the skin and/or its appendages or mucous membranes, which has a pleasant colour, odour and feel and which does not generate unacceptable discomfort (stinging, tautness, redness) that may dissuade the consumer from using this composition.
• keratinous substances is intended to mean the skin (body, face, area around the eyes), hair, eyelashes, eyebrows, body hair, nails, lips or mucosa.
• Bacteriocins are peptide compounds synthesized naturally by certain bacteria. They play an important role in the competition between bacterial strains.
• Bacteriocins may be bactericidal, i.e. eliminate certain microorganisms, and/or they may be bacteriostatic, i.e. inhibit the growth of certain microorganisms.
• the bactericidal or bacteriostatic activity is directed against certain species close to the producer strain.
• Bacteriocins are generally cationic and amphiphilic peptides responsible for the permeabilisation of the membrane of target cells. Specifically, they bind to certain membrane receptors and cause thereon the formation of pores. The membrane is thus made permeable to certain compounds such as ions or molecules. This is generally lethal for the target bacterium. Bacteriocin classification
• Bacteriocins are classified, according to structural data, into four classes, as proposed by Klaenhammer (1993). These four classes are: Class I: Lantibiotics: heat-stable peptides less than 5 kDa in size, which contain unusual sulphur-containing amino acids formed post-translationally, i.e. lanthionine, ⁇ -methyllanthionine, dehydrobutyrine and dehydroalanine.
• class la which comprises elongated hydrophobic cationic peptides containing up to 34 amino acids
• class lb which comprises globular peptides which are negatively charged or which have no net charge and which contain up to 19 amino acids
• Two-component class I bacteriocins also exist, such as cytolysin, lacticin 3147 and plantaricin W (cf. Table 3).
• class I bacteriocins that can be used according to the invention, mention may be made of nisin, epidermin, subtilin, lactocin S, salivaricin A and plantaricin C.
• Lacticin 347 (A1 and A2) Lactococcus lactis DPC3147 Dougherty ef al., 1998
• Class II is divided into three subclasses.
• the subclass lla bacteriocins are peptides which have a structure similar to that of pediocin, which was the first bacteriocin of this group that was described.
• the subclass I la bacteriocins contain between 27 and 48 amino acids and all have a hydrophobic N-terminal portion containing the YGNGV consensus sequence and also a disulphide bridge, and a less conserved, hydrophobic or amphiphilic C-terminal portion which determines the specificity of action (Fimland et al., 2000; Richard et al., 2006).
• This class can also more particularly be defined as having in particular a conserved N-terminal sequence YGNGVxCxxxxCxV (Klaenhammer, 1993; Ennahar et al. 2000; Nes and Holo, 2000). They all have an anti-Listeria activity. Some bacteriocins of this subclass also contain a second disulphide bridge in their C-terminal domain, which appears to be important in stabilising the tertiary structure. It appears, moreover, that it gives them a better antimicrobial activity, better resistance to exposure to high temperatures and a broader spectrum of action (Eijsink et al., 1998; Fimland et al., 2000; Drider et al., 2006; Richard et al., 2006).
• the Mb subclass comprises the bacteriocins that need two peptides in order to have an activity.
• Two types of class Mb bacteriocins can be distinguished: type E (Enhancing), where the function of one of the two peptides is to increase the activity of the other, and type S (Synergy), where the two peptides are complementary.
• the lie subclass contains the bacteriocins that cannot be classified in the other subclasses.
• class I la bacteriocins that can be used according to the invention, mention may be made of the bacteriocins in Table 5. Mention may also be made of coagulin.
• class lib bacteriocins that can be used according to the invention, mention may be made of lactococcin G, lactacin, lactocin 705, thermophilin, plantaricin EF, leucocin, carnocin and acidocin. Mention may more particularly be made of the bacteriocins listed in Table 6 below.
• class lie bacteriocins that can be used according to the invention, mention may be made of the bacteriocins listed in Table 7 below. Table 7: Examples of class lie bacteriocins
• Plantaricin 149 is a class II bacteriocin consisting of sequence YSLQMGATAIKQVKKLFKKKGG (SEQ ID NO:20).
• bacteriocins Heat-sensitive proteins greater than 30 kDa in size. The structure and the mode of action of these bacteriocins differ completely from the other bacteriocins produced by lactic acid bacteria. To date, four bacteriocins of this class have been identified: helveticin J produced by Lactobacillus helveticus A, enterolysin A produced by Enterococcus faecium, zoocin A produced by Streptococcus zooepidemicus and millericin B produced by Streptococcus milleri (Nilsen et al., 2003; Papagianni, 2003; Nigutova et al., 2007).
• class III bacteriocins that can be used according to the invention, mention may be made of the bacteriocins listed in Table 8 below.
• Class IV Peptides requiring a carbohydrate or lipid portion in order to have an activity. No bacteriocin of this class has been described.
• the bacteriocins used in the present invention can be produced by any suitable method known to those skilled in the art. They can be synthesized without difficulty by those skilled in the art, using the conventional solid-phase or solution peptide synthesis techniques (M. Bodanszky, Principles of Peptide Synthesis, 2 nd ed., 1993, published by Springer-Verlag).
• the bacteriocins used according to the invention can also be produced by microorganisms, using bioengineering methods. In this case, it may be necessary to extract and purify the peptide from the producer microorganisms, before formulation.
• the bacteriocins used according to the invention are synthetic peptides.
• the present invention is directed towards the use of a class II bacteriocin as defined above, as a deodorant agent.
• the bacteriocin used is a class Mb bacteriocin.
• an aspect of the invention is the use of at least one of the class Mb bacteriocins mentioned above, more particularly of a class Mb bacteriocin selected in the group consisting of the bacteriocins listed in Table 4 or 6.
• the bacteriocin used is a class lie bacteriocin.
• an aspect of the invention is the use of at least one of the class lie bacteriocins mentioned above, more particularly of a class lie bacteriocin selected in the group consisting of the bacteriocins listed in Table 4 or 7.
• the bacteriocin used is a class lla bacteriocin.
• an aspect of the invention is the use of at least one of the class lla bacteriocins mentioned above, more particularly of a class lla bacteriocin selected in the group consisting of the bacteriocins listed in Table 4 or 5.
• the class lla bacteriocin is selected in the group consisting of pediocin PA-1 , sakacin A and sakacin P.
• the class II bacteriocin is selected in the group consisting of class II plantaricins.
• the class II plantaricin is selected in the group consisting of plantaricin A, plantaricin C19 and plantaricin 149.
• the class II bacteriocin is plantaricin C19 ou plantaricin 149.
• the class II bacteriocin is used in combination with another class II bacteriocin.
• a class lla bacteriocin is used in combination with another class II bacteriocin, for example with another class lla bacteriocin, or with a class Mb and/or lie bacteriocin.
• the class II for example class lla, Mb or lie, preferably class lla, bacteriocin is used in combination with a bacteriocin of another class, for example a class I bacteriocin and/or a class III bacteriocin.
• the invention relates to the use of a class II, in particular a class lla bacteriocin or a class II plantaricin, bacteriocin in combination with a class I bacteriocin.
• the class I bacteriocin may in particular be selected from those mentioned above.
• the class I bacteriocin may be selected in the group consisting of the bacteriocins listed in Tables 1 , 2 and 3.
• the invention relates to the use of a class lla bacteriocin selected in the group consisting of the bacteriocins listed in Table 4 or 5, in combination with a class I bacteriocin selected in the group consisting of the bacteriocins listed in Tables 1 , 2 and 3.
• the class lla bacteriocin is selected in the group consisting of pediocin PA-1 , sakacin A and sakacin P, and the class I bacteriocin is selected in the group consisting of nisin A, epidermin, salivaricin, plantaricin C and gallidermin.
• the class II plantaricin is selected in the group consisting of plantaricin A, plantaricin C19 and plantaricin 149
• the class I bacteriocin is selected in the group consisting of nisin A, epidermin, salivaricin, plantaricin C and gallidermin.
• the invention relates to the use of a class II, in particular a class lla bacteriocin or a class II plantaricin, bacteriocin in combination with a class III bacteriocin.
• the class lla bacteriocin is selected in the group consisting of the bacteriocins listed in Table 4 or 5.
• the class lla bacteriocin is selected in the group consisting of pediocin PA-1 , sakacin A and sakacin P.
• the class II plantaricin is selected in the group consisting of plantaricin A, plantaricin C19 and plantaricin 149.
• Another aspect of the invention relates to the use of a class III bacteriocin as defined above, as a deodorant agent. More specifically, the invention thus relates to the use of a class III bacteriocin selected in the group consisting of helveticin J, enterolysin A, zoocin A and millericin B.
• the class III bacteriocin can also be used in combination with a class I or class II, in particular a class lla bacteriocin or a class II plantaricin, as defined above.
• the invention also relates to a cosmetic composition for treating unpleasant human body odours, in particular unpleasant axillary odours, comprising, in a cosmetically acceptable medium, a class II bacteriocin, for example a class lla, Mb or lie bacteriocin.
• a class II bacteriocin for example a class lla, Mb or lie bacteriocin.
• the class II bacteriocin is a class lla bacteriocin or a class II plantaricin.
• the composition according to the invention comprises a class lla bacteriocin as defined above or a class II plantaricin (e.g. plantaricin A, plantaricin C19 or plantaricin 149).
• the invention relates to a composition comprising, in a cosmetically acceptable medium, a class lla bacteriocin selected in the group consisting of the bacteriocins listed in Table 4 or 5.
• the class lla bacteriocin is selected in the group consisting of pediocin PA-1 , sakacin A and sakacin P.
• the composition according to the invention also comprises at least one class I or III bacteriocin.
• the composition according to the invention comprises the combination of a class II bacteriocin, preferably a class lla bacteriocin or a class II plantaricin, in particular selected in the group consisting of the bacteriocins listed in Table 4 or 5, with a class I bacteriocin selected in the group consisting of the bacteriocins listed in Tables 1 , 2 and 3.
• the class I bacteriocin is selected in the group consisting of nisin A, epidermin, salivaricin, plantaricin C and gallidernnin.
• the composition according to the invention comprises:
• a class lla bacteriocin selected in the group consisting of pediocin PA-1 , sakacin A and sakacin P, or a class II plantaricin selected in the group consisting of plantaricin A, plantaricin C19 and plantaricin 149, and
• class I bacteriocin selected in the group consisting of nisin A, epidermin, salivaricin, plantaricin C and gallidernnin.
• the composition according to the invention comprises a class lla bacteriocin, in particular one of those described in Tables 4 and 5, or a class II plantaricin, in particular plantaricin A, plantaricin C19 or plantaricin 149, in combination with a class III bacteriocin.
• the invention also relates to a cosmetic composition for treating unpleasant human body odours, in particular unpleasant axillary odours, comprising a class III bacteriocin in a cosmetically acceptable medium.
• the class III bacteriocin may be combined, in the composition, with a class I or class II, preferably class I la bacteriocin as defined above or class II plantaricin (e.g.
• the composition comprises a class III bacteriocin, in particular one of the four mentioned above, in combination with a class I la bacteriocin selected in the group consisting of pediocin PA-1 , sakacin A and sakacin P.
• the composition comprises a class III bacteriocin, in particular one of the four mentioned above, in combination with a class II plantaricin selected in the group consisting of plantaricin A, plantaricin C19 and plantaricin 149.
• the class I bacteriocin may more particularly be selected from the group of the bacteriocins described in Tables 1 , 2 and 3.
• the composition comprises a class III bacteriocin, in particular one of the four mentioned above, in combination with a class I bacteriocin selected in the group consisting of nisin A, epidermin, salivaricin, plantaricin C and gallidermin.
• each bacteriocin present in the compositions according to the invention can be present at a concentration of between 0.0001 % and 1 % of active material, relative to the composition.
• the invention also relates to a cosmetic method for treating body odours, in particular axillary odours, which comprises applying to the keratinous substances a composition as described above.
• the process according to the invention comprises the application of a composition comprising a class II, preferably class I la, bacteriocin according to each of the embodiments and variants of this composition described above.
• bacteriocins in products intended for combating in particular C. xerosis, which is a Gram+ bacterium, is one particular embodiment of the invention. Destroying or inhibiting the bacteria responsible for unpleasant odours, and in particular unpleasant axillary odours, makes it possible to reduce and/or remove or prevent the development of body odours without, however, destroying the ecosystem of the area treated. Those skilled in the art will be able to adjust the strength of the deodorising effect by selecting the bacteriocins most active against one or more microorganisms responsible for unpleasant body odours.
• compositions according to the invention can independently be in the form of suspensions, dispersions, solutions, gels, emulsions (in particular of liquid or semi- liquid, soft, semi-solid or solid consistency), in particular oil-in-water (O/W), wax-in- water or water-in-oil (W/O) emulsions, or multiple (W/O/W or polyol/O/W or O/W/O) emulsions, or in the form of creams, pastes, foams, microemulsions, dispersions of vesicles, in particular of ionic or nonionic lipids, wax/aqueous phase dispersions, two- phase or multiphase lotions, or pastes, in particular flexible pastes. They can in particular be in the form of aqueous gels or of aqueous or aqueous-alcoholic solutions.
• compositions according to the invention or used in the method according to the invention can be in the form of a protecting, treating or care composition for the face, for the hands or for the body (for example, day creams, night creams, makeup- removing creams, antisun compositions, body protection or care milks, aftersun milks, skincare lotions, gels or foams); or an aftershave composition.
• compositions are compositions for covering the skin of the body or the face, more particularly makeup or care compositions for the skin of the body or the face, such as, for example, foundations or body makeup compositions.
• suitable galenic form and also the method for preparing same, according to their general knowledge, taking into account, firstly, the nature of the constituents used, in particular their solubility in the carrier, and, secondly, the application contemplated for each composition.
• compositions can in particular be packaged in pressurised form in an aerosol device or in a pump-dispenser; packaged in a device fitted with a perforated wall, in particular a grille; packaged in a roll-on device; packaged in the form of sticks, or in the form of loose or compacted powder; or else applied on wipes.
• the compositions may also be in the form of soaps or gels (rinse-off or leave-on). In this respect, they contain the ingredients generally used in products of this type and which are well known to those skilled in the art.
• compositions according to the invention may be anhydrous.
• An anhydrous composition according to the invention may in particular be in the form of a stick a cream, a soft solid or an aerosol.
• anhydrous composition is intended to mean a composition containing less than 2% by weight of water, or even less than 0.5% of water, and in particular free of water, the water not being added during the preparation of the composition, but corresponding to the residual water introduced by the ingredients that are mixed.
• compositions according to the invention may be in the form of solid compositions, in particular in the form of a stick.
• solid composition is intended to mean that the measurement of the maximum force measured by texturometry during insertion of a probe down into the formulation sample should be at least equal to 0.25 newton, in particular at least equal to 0.30 newton, especially at least equal to 0.35 newton, assessed under precise measuring conditions as follows.
• the formulations are hot-cast into pots 4 cm in diameter and 3 cm deep. Cooling is carried out at ambient temperature. The hardness of the formulations prepared is measured after a standing period of 24 hours.
• the pots containing the samples are characterized by texturometry using a texturometer such as the one sold by the Rheo company, TA-XT2, according to the following protocol: a probe of stainless steel bead type, 5 mm in diameter, is brought into contact with the sample at a speed of 1 mm/s. The measuring system detects the interface with the sample with a detection threshold equal to 0.005 newton. The probe is pushed down 0.3 mm into the sample, at a speed of 0.1 mm/s. The measuring apparatus records the change in the compression force measured over time, during the penetration phase. The hardness of the sample corresponds to the average of the maximum values of the force detected during the penetration, over at least 3 measurements.
• a texturometer such as the one sold by the Rheo company, TA-XT2
• composition according to the invention can be aqueous.
• the composition preferably has a pH of between 3 and 9, depending on the carrier selected.
• the compositions according to the invention which are intended for cosmetic use can comprise at least one aqueous phase. They are in particular formulated as aqueous lotions or as water-in-oil or oil-in-water emulsion, or as a multiple emulsion (oil-in- water-in-oil or water-in-oil-in-water triple emulsion) (such emulsions are known and described, for example, by C. Fox in "Cosmetics and Toiletries” - November 1986 - Vol. 101 - pages 101 -1 12).
• the aqueous phase of said compositions contains water and, in general, other water- soluble or water-miscible solvents.
• the water-soluble or water-miscible solvents include short-chain monoalcohols for example of Ci-C 4 , such as ethanol or isopropanol; diols or polyols, such as ethylene glycol, 1 ,2-propylene glycol, 1 ,3- butylene glycol, hexylene glycol, diethylene glycol, dipropylene glycol, 2- ethoxyethanol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether and sorbitol.
• Propylene glycol, glycerol and propane-1 ,3-diol will more particularly be used.
• emulsifiers that may be used in the oil-in-water emulsions or oil-in-water-in-oil triple emulsions, mention may be made, for example, of nonionic emulsifiers such as oxyalkylenated (more particularly polyoxyethylenated) esters of fatty acid and glycerol; oxyalkylenated esters of fatty acid and sorbitan; oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty acid esters; oxyalkylenated (oxyethylenated and/or oxypropylenated) fatty alcohol ethers; sugar esters such as sucrose stearate; and mixtures thereof such as the mixture of glyceryl stearate and PEG-40 stearate.
• nonionic emulsifiers such as oxyalkylenated (more particularly polyoxyethylenated) esters of fatty acid and
• emulsifiers that can be used in the water-in-oil emulsions or triple emulsions (H/W/H or W/H/W)
• Ri denotes a C12-C20, and preferably C12-C18, linear or branched alkyl group
• R 2 denotes the group: ⁇ CnH2n ⁇ (-OC2H 4 -) x ⁇ (-OC 3 H6-)y ⁇ O— R 3 ;
• R3 denotes a hydrogen atom or a linear or branched alkyl radical containing from 1 to
• a is an integer ranging from 1 to approximately 500;
• b denotes an integer ranging from 1 to approximately 500;
• n is an integer ranging from 2 to 12, and preferably 2 to 5;
• x denotes an integer ranging from 1 to approximately 50, and preferably from 1 to 30; y denotes an integer ranging from 0 to approximately 49, and preferably 0 to 29, with the proviso that, when y is different from zero, the ratio x/y is greater than 1 , and preferably ranges from 2 to 1 1 .
• cetyl PEG/PPG-10/1 Dimethicone and more particularly the mixture Cetyl PEG/PPG-10/1 Dimethicone and Dimethicone (INCI name), for instance the product sold under the trade name Abil EM90 by the Goldschmidt or else the (Polyglyceryl-4-stearate and Cetyl PEG/PPG-10 (and) Dimethicone (and) Hexyl Laurate) mixture, for instance the product sold under the trade name Abil WE09 by the same company.
• R 4 denotes the group: ⁇ C m H 2 m ⁇ (-OC2H 4 -) s ⁇ (-OC 3 H6-)t ⁇ O— R 5 ;
• R 5 denotes a hydrogen atom or a linear or branched alkyl radical containing from 1 to
• d denotes an integer ranging from 1 to approximately 500;
• n is an integer ranging from 2 to 12, and preferably 2 to 5;
• s denotes an integer ranging from 1 to approximately 50, and preferably from 1 to 30
• t denotes an integer ranging from 0 to approximately 50, and preferably from 0 to 30; with the proviso that the sum s+t is greater than or equal to 1 .
• dimethicone copolyol emulsifiers of formula (II) use will particularly be made of PEG-18/PPG-18 Dimethicone, and more particularly the Cyclopentasiloxane (and) PEG-18/PPG-18 Dimethicone mixture (INCI name), such as the product sold by Dow Corning under the trade name Silicone DC 5225 C or KF-6040 from Shin Etsu.
• a mixture of at least one emulsifier of formula (I) and at least one emulsifier of formula (II) will be used.
• Use will more particularly be made of a mixture of PEG-18/PPG-18 Dimethicone and Cetyl PEG/PPG-10/1 Dimethicone, and even more particularly a mixture of (Cyclopentasiloxane (and) PEG-18/PPG-18 Dimethicone) and of Cetyl PEG/PPG-10/1 Dimethicone and Dimethicone or of (Polyglyceryl-4-stearate and Cetyl PEG/PPG-10 (and) Dimethicone (and) Hexyl Laurate).
• water-in-oil emulsifiers mention may also be made of the nonionic emulsifiers derived from a fatty acid and from a polyol, alkylpolyglycosides (APGs), sugar esters, and mixtures thereof.
• APGs alkylpolyglycosides
• nonionic emulsifiers derived from a fatty acid and from a polyol use may in particular be made of fatty acid esters of a polyol, the fatty acid having in particular a Cs-C2 4 alkyl chain, and the polyols being, for example, glycerol and sorbitan.
• fatty acid esters of a polyol mention may in particular be made of isostearic acid esters of polyols, stearic acid esters of polyols, and mixtures thereof, in particular isostearic acid esters of glycerol and/or of sorbitan.
• stearic acid esters of polyols mention may in particular be made of polyethylene glycol esters, for instance PEG-30 dipolyhydroxystearate, such as the product sold under the name Arlacel P135 by ICI.
• glycerol and/or sorbitan esters mention may, for example, be made of polyglyceryl isostearate, such as the product sold under the name Isolan Gl 34 by Goldschmidt; sorbitan isostearate, such as the product sold under the name Arlacel 987 by ICI; glycerol sorbitan isostearate, such as the product sold under the name Arlacel 986 by ICI; the mixture of sorbitan isostearate and polyglyceryl isostearate (3 mol) sold under the name Arlacel 1690 by Uniqema, and mixtures thereof.
• polyglyceryl isostearate such as the product sold under the name Isolan Gl 34 by Goldschmidt
• sorbitan isostearate such as the product sold under the name Arlacel 987 by ICI
• glycerol sorbitan isostearate such as the product sold under the name Arlacel 986 by ICI
• the emulsifier may also be selected from alkylpolyglycosides having an HLB of less than 7, for example those represented by general formula (1 ) below:
• the unsaturated alkyl radical may comprise one or more ethylenic unsaturations, and in particular one or two ethylenic unsaturations.
• This alkylpolyglucoside may be used as a mixture with a coemulsifier, more especially with a fatty alcohol, and in particular a fatty alcohol having the same fatty chain as that of the alkylpolyglucoside, i.e. containing from 14 to 24 carbon atoms and having a branched and/or unsaturated chain, and for example isostearyl alcohol when the alkylpolyglucoside is isostearylglucoside, and oleyl alcohol when the alkylpolyglucoside is oleylglucoside, optionally in the form of a self-emulsifying composition, as described, for example, in document WO-A-92/06778.
• polyolefins with a succinic end group such as polyisobutylenes with an esterified succinic end group and salts thereof, in particular the diethanolamine salts, such as the products sold under the names Lubrizol 2724, Lubrizol 2722 and Lubrizol 5603 by the company Lubrizol or the commercial product Chemcinnate 2000.
• the total amount of emulsifiers in the composition will preferably, in the composition according to the invention, be in contents with respect to active material ranging from 1 % to 8% by weight, and more particularly from 2% to 6% by weight, relative to the total weight of the composition.
• the leave-on compositions according to the invention may contain at least one water-immiscible organic liquid phase, called fatty phase.
• the latter comprises, in general, one or more hydrophobic compounds which render said phase water- immiscible.
• Said phase is liquid (in the absence of structuring agent) at ambient temperature (20-25°C).
• the water-immiscible organic liquid phase in accordance with the invention generally comprises at least one volatile oil and/or one non-volatile oil and, optionally, at least one structuring agent.
• oil is intended to mean a fatty substance which is liquid at ambient temperature (25°C) and atmospheric pressure (760 mmHg, i.e. 10 5 Pa).
• the oil may be volatile or non-volatile.
• volatile oil is intended to mean an oil capable of evaporating on contact with the skin or with the keratin fibre in less than one hour, at ambient temperature and atmospheric pressure.
• the volatile oils of the invention are volatile cosmetic oils which are liquid at ambient temperature and which have a nonzero vapour pressure, at ambient temperature and atmospheric pressure, ranging in particular from 0.13 Pa to 40 000 Pa (10 "3 to 300 mmHg), in particular ranging from 1 .3 Pa to 13 000 Pa (0.01 to 100 mmHg), and more particularly ranging from 1 .3 Pa to 1300 Pa (0.01 to 10 mmHg).
• non-volatile oil is intended to mean an oil which remains on the skin or the keratin fibre at ambient temperature and atmospheric pressure for at least several hours and which has in particular a vapour pressure of less than 10 "3 mmHg (0.13 Pa).
• the oil may be selected from any of the physiologically acceptable, and in particular cosmetically acceptable, oils, especially mineral, animal, plant or synthetic oils; in particular volatile or non-volatile, hydrocarbon-based and/or silicone and/or fluoro oils and mixtures thereof.
• hydrocarbon-based oil is intended to mean an oil comprising mainly carbon and hydrogen atoms and, optionally, one or more functions selected from hydroxyl, ester, ether and carboxylic functions.
• the oil has a viscosity of from 0.5 to 100 000 mPa.s, preferably from 50 to 50 000 mPa.s, and more preferably from 100 to 30 000 mPa.s.
• volatile hydrocarbon-based oils selected from hydrocarbon-based oils containing from 8 to 16 carbon atoms, and in particular Cs-Ci6 isoalkanes of petroleum origin (also known as isoparaffins), such as isododecane (also known as 2,2,4,4,6-pentamethylheptane), isodecane or isohexadecane, and for example the oils sold under the trade names Isopars or Permetyls, Cs-Ci6 branched esters, isohexyl neopentanoate, and mixtures thereof.
• Other volatile hydrocarbon-based oils such as petroleum distillates, in particular those sold under the name Shell Solt by the company Shell, may also be used; volatile linear alkanes such as those described in patent application DE 10 2008 012 457 from the company Cognis;
• volatile silicones for instance volatile linear or cyclic silicone oils, in particular those having a viscosity ⁇ 8 centistokes (8 x 10 "6 m 2 /s), and having in particular from 2 to 7 silicon atoms, these silicones optionally comprising alkyl or alkoxy groups containing from 1 to 10 carbon atoms.
• volatile silicone oil that can be used in the invention, mention may in particular be made of octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, heptamethylhexyl- trisiloxane, heptamethyloctyltrisiloxane, hexamethyldisiloxane, octamethyltrisiloxane, decamethyltetrasiloxane, dodecamethylpentasiloxane;
• R (Hi) where R represents an alkyl group containing from 2 to 4 carbon atoms, and one or more hydrogen atoms of which may be substituted with a fluorine or chlorine atom.
• hydrocarbon-based oils of animal origin such as perhydrosqualene
• plant hydrocarbon-based oils such as liquid triglycerides of fatty acids containing from 4 to 24 carbon atoms, such as heptanoic or octanoic acid triglycerides, or else wheat germ oil, olive oil, sweet almond oil, palm oil, rapeseed oil, cottonseed oil, alfalfa oil, poppy oil, pumpkin oil, marrow oil, blackcurrant oil, evening primrose oil, millet oil, barley oil, quinoa oil, rye oil, saffron oil, candlenut oil, passion flower oil, musk rose oil, sunflower oil, maize oil, soybean oil, grapeseed oil, sesame oil, hazelnut oil, apricot oil, macadamia oil, castor oil, avocado oil, caprylic/capric acid triglycerides such as those sold by the company Stearineries Dubois or those sold under the names Miglyol 810, 812 and 818 by the company Dynamit Nobel, jojoba
• linear or branched hydrocarbons of inorganic or synthetic origin such as liquid paraffins and derivatives thereof, petroleum jelly, polydecenes, polybutenes, hydrogenated polyisobutene such as sesam, or squalane;
• esters in particular of fatty acids, such as oils of formula R1COOR2 in which Ri represents a linear or branched higher fatty acid residue containing from 1 to 40 carbon atoms and R2 represents an in particular branched hydrocarbon- based chain containing from 1 to 40 carbon atoms, with Ri + R 2 > 10, for instance purcellin oil (cetostearyl octanoate), isononyl isononanoate, isopropyl myristate, isopropyl palmitate, C12 - C15 alkyl benzoate, hexyl laurate, diisopropyl adipate, 2- ethylhexyl palmitate, 2-octyldodecyl stearate, 2-octyldodecyl erucate, isostearyl isostearate, tridecyl trimellitate; alkyl or polyalkyl octanoates, decanoates or ricino
• fatty alcohols that are liquid at ambient temperature, comprising a branched and/or unsaturated carbon-based chain containing from 12 to 26 carbon atoms, such as octyldodecanol, isostearyl alcohol, 2-butyloctanol, 2-hexyldecanol, 2- undecylpentadecanol or oleyl alcohol;
• higher fatty acids such as oleic acid, linoleic acid or linolenic acid
• fluoro oils optionally partially hydrocarbon-based and/or silicone-based, such as fluorosilicone oils, fluorinated polyethers or fluorinated silicones, as described in document EP-A-847752;
• silicone oils such as polydimethylsiloxanes (PDMS) which are non-volatile and linear or cyclic; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups which are pendant or at the end of the silicone chain, said groups having from 2 to 24 carbon atoms; phenylated silicones such as phenyl trimethicones, phenyl dimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyl dimethicones, diphenylmethyldiphenyltrisiloxanes or 2-(phenylethyl)trimethylsiloxysilicates, and
• compositions according to the invention comprising a fatty phase may also contain at least one structuring agent for said fatty phase which may be selected preferably from waxes, pasty compounds, inorganic or organic lipophilic gelling agents, and mixtures thereof. It is understood that the amount of these compounds can be adjusted by those skilled in the art in such a way as to not be detrimental to the desired effect in the context of the present invention.
• Wax is, in general, a lipophilic compound which is solid at ambient temperature (25°C), which has a reversible solid/liquid change in state and which has a melting point of greater than or equal to 30°C, which can go up to 200°C and in particular up to 120°C.
• the waxes suitable for the invention may have a melting point of greater than or equal to 45°C, and in particular greater than or equal to 55°C.
• the melting point corresponds to the temperature of the most endothermic peak observed by thermal analysis (DSC) as described in ISO Standard 1 1357-3; 1999.
• the melting point of the wax can be measured using a differential scanning calorimeter (DSC), for example the calorimeter sold under the name "MDSC 2920" by the company TA Instruments.
• the measurement protocol is as follows:
• a 5 mg sample of wax placed in a crucible is subjected to a first rise in temperature ranging from -20°C to 100°C at a heating rate of 10°C/minute, and is then cooled from 100°C to -20°C at a cooling rate of 10°C/minute and, finally, is subjected to a second rise in temperature ranging from -20°C to 100°C at a heating rate of 5°C/minute.
• the variation in the difference in power absorbed by the empty crucible and by the crucible containing the sample of wax is measured as a function of the temperature.
• the melting point of the compound is the value of the temperature corresponding to the tip of the peak of the curve representing the variation in the difference in power absorbed as a function of the temperature.
• the waxes that can be used in the compositions according to the invention are selected from waxes, which are solid at ambient temperature, of animal, plant, mineral or synthetic origin, and mixtures thereof.
• waxes suitable for the invention mention may in particular be made of hydrocarbon-based waxes such as beeswax, lanolin wax, and Chinese insect waxes, rice bran wax, carnauba wax, candelilla wax, ouricury wax, Alfa wax, berry wax, shellac wax, Japan wax and sumach wax; montane wax, orange and lemon waxes, the refined sunflower wax sold under the name Sunflower Wax by Koster Keunen, microcrystalline waxes, paraffins and ozokerites; polyethylene waxes, waxes obtained by Fischer Tropsch synthesis and waxy copolymers, and also esters thereof.
• waxes obtained by catalytic hydrogenation of animal or plant oils containing linear or branched C8-C32 fatty chains may also be made.
• isomerised jojoba oil such as the trans-isomerised partially hydrogenated jojoba oil manufactured or sold by the company Desert Whale under the commercial reference lso-Jojoba-50 ® , hydrogenated sunflower oil, hydrogenated castor oil, hydrogenated coconut oil, hydrogenated lanolin oil, and the di-(1 ,1 ,1 -trimethylolpropane) tetrastearate sold under the name Hest 2T-4S ® by the company Heterene.
• silicone waxes C3o -4 5 Alkyl Dimethicone
• fluoro waxes C3o -4 5 Alkyl Dimethicone
• waxes obtained by hydrogenation of castor oil esterified with cetyl alcohol sold under the names Phytowax ricin 16L64 ® and 22L73 ® by the company Sophim. Such waxes are described in application FR-A-2792190.
• Use may be made, as wax, of a C2o-C 4 o alkyl (hydroxystearyloxy)stearate (the alkyl group containing from 20 to 40 carbon atoms), alone or as a mixture.
• a wax is in particular sold under the names Kester Wax K 82 P ® , Hydroxypolyester K 82 P ® and Kester Wax K 80 P ® by the company Koster Keunen.
• microwaxes that can be used in the compositions according to the invention, mention may in particular be made of carnauba microwaxes such as the product sold under the name MicroCare 350 ® by the company Micro Powders, microwaxes of synthetic wax, such as the product sold under the name MicroEase 1 14S ® by the company Micro Powders, microwaxes constituted of a mixture of carnauba wax and polyethylene wax, such as those sold under the names MicroCare 300 ® and 310 ® by the company Micro Powders, microwaxes constituted of a mixture of carnauba wax and of synthetic wax, such as the product sold under the name MicroCare 325 ® by the company Micro Powders, polyethylene microwaxes such as those sold under the names Micropoly 200 ® , 220 ® , 220L ® and 250S ® by the company Micro Powders, the commercial products Performalene 400 Polyethylene and Performalene 500-L Polyethylene from New Phase Technologies, Performalene 655 Polyethylene or paraffin waxe
• composition according to the invention will preferably comprise a content of wax(es) ranging from 3% to 20% by weight, relative to the total weight of the composition, in particular from 5% to 15%, more particularly from 6% to 15%.
• anhydrous solid compositions in the form of a stick use will be made of polyethylene microwaxes in the form of crystallites having a shape factor at least equal to 2 and having a melting point ranging from 70 to 1 10°C, and preferably 70 to 100°C, in order to reduce or even eliminate the presence of strata in the solid composition.
• These needle-shaped crystallites can be characterized visually according to the following method.
• the wax is deposited on a microscope slide, which is placed on a heated platform.
• the slide and the wax are heated to a temperature which is generally at least 5°C above that of the melting point of the wax or of the wax mixture under consideration.
• the liquid thus obtained and the microscope slide are left to cool in order to solidify.
• the crystallites are observed using a Leica DMLB100 optical microscope, with an objective selected according to the size of the objects to be visualized, and by polarized light.
• the dimensions of the crystallites are measured using image analysis software, such as the software sold by the company Microvision.
• the crystallite polyethylene waxes in accordance with the invention preferably have an average length ranging from 5 to 10 ⁇ .
• the term "average length" denotes the dimension given by the statistical particle size distribution to half the population, referred to as D50.
• the term "pasty compound” is intended to mean a lipophilic fatty compound that undergoes a reversible solid/liquid change of state, that has an anisotropic crystalline organization in the solid state, and that comprises, at a temperature of 23°C, a liquid fraction and a solid fraction.
• the pasty compound is preferably selected from synthetic compounds and compounds of plant origin.
• a pasty compound may be obtained by synthesis from starting products of plant origin.
• linear or branched oligomers which are homopolymers or copolymers of alkyl (meth)acrylates preferably containing a C8-C30 alkyl group,
• oligomers which are homopolymers and copolymers of vinyl esters containing C8-C30 alkyl groups, and
• oligomers which are homopolymers and copolymers of vinyl ethers containing C 8 -C 3 o alkyl groups
• esters those preferred are:
• - esters of a glycerol oligomer especially diglycerol esters, in particular condensates of adipic acid and of glycerol, for which some of the hydroxyl groups of the glycerols have reacted with a mixture of fatty acids such as stearic acid, capric acid, stearic acid and isostearic acid, and 12-hydroxystearic acid, in particular such as those sold under the trade mark Softisan 649 by the company Sasol,
• mineral lipophilic gelling agent mention may be made of optionally modified clays such as hectorites modified with a C10 to C22 ammonium chloride, for instance hectorite modified with distearyldimethylammonium chloride, such as, for example, the product sold under the name Bentone 38V ® by the company Elementis.
• optionally modified clays such as hectorites modified with a C10 to C22 ammonium chloride, for instance hectorite modified with distearyldimethylammonium chloride, such as, for example, the product sold under the name Bentone 38V ® by the company Elementis.
• fumed silica optionally hydrophobically surface- treated, the particle size of which is less than 1 ⁇ . It is in fact possible to chemically modify the surface of the silica, by chemical reaction generating a decrease in the number of silanol groups present at the surface of the silica. It is in particular possible to replace silanol groups with hydrophobic groups: a hydrophobic silica is then obtained.
• the hydrophobic groups may be trimethylsiloxyl groups, which are in particular obtained by treatment of fumed silica in the presence of hexamethyldisilazane. Silicas treated in this way are called “Silica Silylate" according to the CTFA (8th Edition, 2000).
• the hydrophobic fumed silica has in particular a particle size that may be nanometric to micrometric, for example ranging approximately from 5 to 200 nm.
• the polymeric organic lipophilic gelling agents are, for example, partially or totally crosslinked elastomeric organopolysiloxanes having a three-dimensional structure, such as those sold under the names KSG6 ® , KSG16 ® and KSG18 ® by the company Shin-Etsu, Trefil E-505C ® and Trefil E-506C ® by the company Dow Corning, Gransil SR-CYC ® , SR DMF 10 ® , SR-DC556 ® , SR 5CYC gel ® , SR DMF 10 gel ® and SR DC 556 gel ® by the company Grant Industries, and SF 1204 ® and JK 1 13 ® by the company General Electric; ethylcellulose, such as the product sold under the name Ethocel ® by the company Dow Chemical; galactomannans comprising from one to six, and in particular from two to four, hydroxyl groups per monosaccharide, substituted with a saturated or uns
• lipophilic gelling agent mention may also be made of polymers with a weight- average molecular weight of less than 100 000, comprising a) a polymeric backbone having hydrocarbon-based repeating units comprising at least one heteroatom and, optionally, b) at least one pendant fatty chain and/or at least one terminal fatty chain, which is (are) optionally functionalized, containing from 6 to 120 carbon atoms and being linked to these hydrocarbon-based units, as described in applications WO-A-02/056847 and WO-A-02/47619, the content of which is incorporated by way of reference; in particular, polyamide resins (especially comprising alkyl groups having from 12 to 22 carbon atoms), such as those described in US-A-5783657, the content of which is incorporated by way of reference.
• polymers with a weight- average molecular weight of less than 100 000 comprising a) a polymeric backbone having hydrocarbon-based repeating units comprising at least one heteroatom and, optionally, b) at
• esters of dextrin and of a fatty acid such as dextrin palmitates, in particular such as those sold under the names Rheopearl TL ® or Rheopearl KL ® by the company Chiba Flour.
• Use may also be made of silicone polyamides of the polyorganosiloxane type, such as those described in documents US-A-5,874,069, US-A-5,919,441 , US-A-6,051 ,216 and US-A-5,981 ,680.
• silicone polymers may belong to the following two families:
• - polyorganosiloxanes comprising at least two groups capable of establishing hydrogen interactions, these two groups being located on grafts or branches.
• compositions of the invention can contain at least one antiperspirant salt or complex.
• the term "agent for treating perspiration" is intended to mean any substance which, by itself, has the effect of reducing the feeling, on the skin, of wetness linked to human sweat or of masking human sweat.
• the antiperspirant salts or complexes in accordance with the invention are generally selected from aluminium and/or zirconium salts or complexes. They are preferably selected from aluminium halohydrates; aluminium zirconium halohydrates, complexes of zirconium hydroxychloride and of aluminium hydroxychloride with or without an amino acid, such as those described in patent US 3 792 068.
• aluminium salts mention may in particular be made of aluminium chlorohydrate in the activated or nonactivated form, aluminium chlorohydrex, the aluminium chlorohydrex polyethylene glycol complex, the aluminium chlorohydrex propylene glycol complex, aluminium dichlorohydrate, the aluminium dichlorohydrex polyethylene glycol complex, the aluminium dichlorohydrex propylene glycol complex, aluminium sesquichlorohydrate, the aluminium sesquichlorohydrex polyethylene glycol complex, the aluminium sesquichlorohydrex propylene glycol complex, or aluminium sulphate buffered with sodium aluminium lactate.
• aluminium zirconium salts mention may in particular be made of aluminium zirconium octachlorohydrate, aluminium zirconium pentachlorohydrate, aluminium zirconium tetrachlorohydrate or aluminium zirconium trichlorohydrate.
• the complexes of zirconium hydroxychloride and of aluminium hydroxychloride with an amino acid are generally known under the name ZAG (when the amino acid is glycine).
• ZAG when the amino acid is glycine.
• these products mention may be made of the aluminium zirconium octachlorohydrex glycine, aluminium zirconium pentachlorohydrex glycine, aluminium zirconium tetrachlorohydrex glycine and aluminium zirconium trichlorohydrex glycine complexes.
• the antiperspirant salts or complexes may be present in the composition according to the invention in a proportion of approximately 0.5% to 25% by weight relative to the total weight of the composition.
• compositions according to the invention may also contain one or more additional deodorant active agents.
• deodorant active agent is used for any substance capable of masking, absorbing, improving and/or reducing the unpleasant odour resulting from the decomposition of human sweat by bacteria.
• the deodorant active agents may be bacteriostatic agents or bactericidal agents which act on the microorganisms of axillary odours, such as 2,4,4'-trichloro-2'- hydroxydiphenyl ether (Triclosan ® ), le 2,4-dichloro-2'-hydroxydiphenyl ether, 3',4',5'- trichlorosalicylanilide, 1 -(3',4'-dichlorophenyl)-3-(4'-chlorophenyl)urea (Triclocarban ® ) or 3,7,1 1 -trimethyldodeca-2, 5,10-trienol (Farnesol ® ); quaternary ammonium salts such as cetyltrimethylammonium salts or cetylpyridinium salts, DPTA (1 ,3- diaminopropanetetraacetic acid), 1 ,2-decanediol (Sym
• deodorant active agents in accordance with the invention, mention may also be made of:
• zinc salts such as zinc salicylate, zinc gluconate, zinc pidolate; zinc sulphate, zinc chloride, zinc lactate, zinc phenolsulphonate; zinc ricinoleate;
• the deodorant active agents may be present preferably in the compositions according to the invention in weight concentrations ranging from 0.01 % to 5% by weight relative to the total weight of the composition.
• one or more suspending agents which are preferably selected from hydrophobic modified montmorillonite clays, such as hydrophobic modified bentonites or hectorites.
• hydrophobic modified montmorillonite clays such as hydrophobic modified bentonites or hectorites.
• CTFA name Stearalkonium Bentonite
• Tixogel MP 250 by the company Sud Chemie Rheologicals, United Catalysts Inc.
• CTFA name Disteardimonium Hectorite
• Bentone 38 or Bentone Gel by the company Elementis Specialities.
• the suspending agents are preferably present in amounts ranging from 0.1 % to 5% by weight, and more preferably from 0.2% to 2% by weight, relative to the total weight of the composition.
• compositions according to the invention will also contain an organic powder.
• organic powder is intended to mean any solid which is insoluble in the medium at ambient temperature (25°C).
• organic powders that can be used in the composition of the invention, mention may, for example, be made of polyamide particles, and in particular those sold under the name Orgasol by the company Atochem; polyethylene powders; microspheres based on acrylic copolymers, such as those made of ethylene glycol dimethacrylate/lauryl methacrylate copolymer, sold by the company Dow Corning under the name Polytrap; microspheres of poly(methyl methacrylate), sold under the name Microsphere M-100 by the company Matsumoto or under the name Covabead LH85 by the company Wackherr; hollow poly(methyl methacrylate) microspheres (particle size: 6.5 - 10.5 ⁇ ) sold under the name Ganzpearl GMP 0800 by Ganz Chemical; methyl methacrylate/ethylene glycol dimethacrylate copolymer microbeads (size: 6.5-10.5 ⁇ ) sold under the name Ganzpearl GMP 0820 by Ganz Chemical or Microsponge 5640 by the company Amcol Health
• the cosmetic compositions according to the invention may also comprise cosmetic adjuvants selected from emollients, antioxidants, opacifiers, stabilizers, moisturizers, vitamins, bactericides, preservatives, polymers, fragrances, thickeners, propellants or any other ingredient normally used in cosmetics for this type of application.
• cosmetic adjuvants selected from emollients, antioxidants, opacifiers, stabilizers, moisturizers, vitamins, bactericides, preservatives, polymers, fragrances, thickeners, propellants or any other ingredient normally used in cosmetics for this type of application.
• the thickeners may be selected from modified or nonmodified guar gums and celluloses, such as hydroxypropyl guar gum or cetylhydroxyethylcellulose, and silicas, for instance Bentone Gel MIO sold by the company NL Industries or Veegum Ultra sold by the company Polyplastic.
• the thickeners may also be cationic, such as, for example, the Polyquaternium-37 sold under the name Salcare SC95 (polyquaternium-37 (and) mineral oil (and) PPG-1 trideceth-6) or Salcare SC96 (polyquaternium-37 (and) propylene glycol dicaprylate/dicaprate (and) PPG-1 -trideceth-6), or other crosslinked cationic polymers such as, for example, those having the CTFA name ethyl acrylate/dimethylamino ethyl methacrylate cationic copolymer in emulsion.
• Salcare SC95 polyquaternium-37 (and) mineral oil (and) PPG-1 trideceth-6)
• Salcare SC96 polyquaternium-37 (and) propylene glycol dicaprylate/dicaprate (and) PPG-1 -trideceth-6
• other crosslinked cationic polymers such as, for example, those having the CTFA name ethy
• the amounts of these various constituents that may be present in the cosmetic composition according to the invention are those conventionally used in compositions for the treatment of perspiration.
• compositions according to the invention may also be pressurized and be packaged in an aerosol device constituted of:
• the propellants generally used in products of this type are, for instance, dimethyl ether (DME), volatile hydrocarbons such as n-butane, propane or isobutane, and mixtures thereof, optionally with at least one chlorinated and/or fluorinated hydrocarbon; among the latter, mention may be made of the compounds sold by the company Dupont de Nemours under the names Freon ® and Dymel ® , and in particular monofluorotrichloromethane, difluorodichloromethane, tetrafluorodichloroethane and 1 ,1 -difluoroethane, sold in particular under the trade name Dymel 152 A by the company Dupont. Carbon dioxide, nitrous oxide, nitrogen or compressed air may also be used as propellant.
• DME dimethyl ether
• volatile hydrocarbons such as n-butane, propane or isobutane, and mixtures thereof, optionally with at least one chlorinated and/orinated hydrocarbon
• compositions containing the perlite particles as defined above and the propellant(s) may be in the same compartment or in different compartments in the aerosol container.
• the pressurized concentration of propellant generally ranges from 5% to 95% by weight, and more preferably from 50% to 85% by weight, relative to the total weight of the pressurized composition.
• the dispensing means which forms part of the aerosol device, is generally constituted of a dispensing valve controlled by a dispensing head, itself comprising a nozzle via which the aerosol composition is vaporized.
• the container containing the pressurized composition may be opaque or transparent. It may be made of glass, of polymer or of metal, optionally covered with a layer of protective lacquer.
• Example 2 Composition for deodorant anhydrous aerosol Ingredients (INCI name) Amounts as % by weight
• the formulation is pressurised with isobutane.
• Example 3 Composition for deodorant/antiperspirant anhydrous aerosol
• Plantaricin A, plantaricin C19, plantaricin 149 (class II bacteriocins) and nisin A (class la bacteriocin) have been tested at a concentration of 100 mg/L in DMSO on the growth of Corynebacterium xerosis (accession No. CIP 100653) and Staphylococcus epidermidis (accession No. ATCC 155).
• Nisin A does not inhibit the growth of C. xerosis or S. epidermidis
• Lag time is respectively 16, 22 and 46 hours for plantaricin A, plantaricin C19 and plantaricin 149, respectively.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Cosmetics (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=42331048

Family Applications (1)

Country Status (4)

Families Citing this family (5)

Family Cites Families (19)

• 2009
  • 2009-12-17 FR FR0959156A patent/FR2954138B1/fr not_active Expired - Fee Related
• 2010
  • 2010-12-17 WO PCT/EP2010/070168 patent/WO2011073438A2/en active Application Filing
  • 2010-12-17 BR BR112012014730A patent/BR112012014730A2/pt not_active Application Discontinuation
  • 2010-12-17 EP EP10795368A patent/EP2512430A2/de not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events